Douglas Arbetter

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Hugh Montgomery, Richard Hobbs, Francisco Padilla et al. · The Lancet Respiratory Medicine · 2022 · 227 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +5

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

C. Michael Gibson, Duane S. Pinto, Gerald Chi et al. · Circulation · 2016 · 95 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients

C. Michael Gibson, Gerald Chi, Rim Halaby et al. · Circulation · 2016 · 68 citations

Medicine, Pharmacology, Pharmacotherapy +17

The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

C. Michael Gibson, Rim Halaby, Serge Korjian et al. · American Heart Journal · 2016 · 55 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

David J. Jackson, Girolamo Pelaia, Benjamin Emmanuel et al. · European Respiratory Journal · 2024 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14